逢跌布局时机已至？港股通创新药ETF(159570)回调超3%交投异常活跃，成交巨幅放量超27亿元，盘中净流入已超5亿元！

Group 1 - The Hong Kong Stock Connect Innovative Drug Index (987018) has decreased by 2.39% as of June 13, 2025, with mixed performance among constituent stocks [1] - The Hong Kong Stock Connect Innovative Drug ETF (159570) has seen a decline of 2.73%, with the latest price at 1.6 yuan, but has increased by 15.96% over the past week [1] - The ETF has a high trading volume, with a turnover of 47.54% and over 2.7 billion yuan in transactions, indicating active market participation [1] Group 2 - The Hong Kong Stock Connect Innovative Drug ETF has reached a new high in scale at 56.22 billion yuan and a new high in shares at 3.448 billion [2] - The ETF has experienced continuous net inflows over the past eight days, totaling nearly 1.2 billion yuan, with a maximum single-day inflow of 234 million yuan [2] - The latest margin buying amount for the ETF is 401 million yuan, with a margin balance of 166 million yuan [2] Group 3 - Recent catalysts in the BD sector and the robust logic of innovative drugs going global suggest a sustained market trend, with continuous recommendations for innovative drugs and Pharma [5] - The ASCO annual meeting highlighted the competitiveness and activity of Chinese pharmaceutical companies in new drug development, with positive market reactions [5] - There is a strong outlook for domestic innovative drugs, particularly for companies with advantages in clinical progress and international expansion [5] Group 4 - The Hong Kong Stock Connect Innovative Drug ETF (159570) has a significant focus on the innovative drug industry, with the top ten holdings accounting for nearly 72% of the total weight [6] - The ETF has a high concentration in innovative drugs, with 85% of its weight in this category, making it one of the highest in the market [6] - The underlying assets are Hong Kong stocks, allowing for T+0 trading, which enhances liquidity [6]